2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with Bone Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H; Cheng, X; Hu, L; Kok, SHL; Lee, KKH; Li, K; Li, P; Lin, L; Qian, F; Song, J; Yang, X; You, L; Zhu, L | 1 |
| Bohr, S; Elman, JS; Hicks, DF; Iwamoto, Y; Luk, S; Murray, R; Parekkadan, B; Pena, K; Seker, E; Sgroi, D; Shen, K; Toner, M; Wang, F; Weissleder, R; Yarmush, ML | 1 |
2 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and Bone Neoplasms
| Article | Year |
|---|---|
Reversine suppresses osteosarcoma cell growth through targeting BMP-Smad1/5/8-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Bone Morphogenetic Proteins; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chick Embryo; G1 Phase Cell Cycle Checkpoints; Human Umbilical Vein Endothelial Cells; Humans; Morpholines; Neovascularization, Physiologic; Osteosarcoma; Purines; Signal Transduction; Smad Proteins; Smad1 Protein; Smad2 Protein; Smad3 Protein | 2021 |
Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Collagen; Disease Progression; Female; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Ki-67 Antigen; Mammary Neoplasms, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Microcirculation; Morpholines; Neoplasm Metastasis; Neoplasm Transplantation; Phenotype; Purines; Signal Transduction; Stromal Cells | 2014 |